Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline
| Autor: | Khashayar Hesamizadeh, Minoo Mohraz, Reza Malekzadeh, Ali Namvar, Mohammad Saeid Rezaee-Zavareh, Mahmood Nabavi, Hossein Poustchi, Seyed Moayed Alavian, Kamran Bagheri Lankarani, Massimo Colombo, Bijan Eghtesad, Mohamad Reza Fattahi, Bita Behnava, Masoud Mardani, Abdul Rahman Bizri, Behzad Hajarizadeh, Nasser Ebrahimi Daryani, Hatef Massoumi, Shahin Merat, Majid Amiri, Masood Ziaee, Mehri Nikbin, Peyman Adibi, Heidar Sharafi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Ledipasvir
medicine.medical_specialty Daclatasvir Consensus Sofosbuvir Context (language use) Review Article Iran 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pegylated interferon medicine 030212 general & internal medicine Intensive care medicine Hepatitis Hepatology business.industry virus diseases Hepatitis C Guideline medicine.disease Virology digestive system diseases Infectious Diseases chemistry Disease Elimination 030211 gastroenterology & hepatology Therapy business medicine.drug |
| Zdroj: | Hepatitis Monthly |
| ISSN: | 1735-3408 1735-143X |
| Popis: | Context: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. Evidence Acquisition: The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, Scopus and Web of Science. Expert opinion was based on the consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016. Results: Pegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. In HCV genotype 1 and 4, DCV/SOF and LDV/SOF are recommended. In HCV genotype 2, SOF plus RBV and in HCV genotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered. Conclusions: Affordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|